08: Antibody Response to RSV Vaccines in Immunocompromised Adults
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
08: Antibody Response to RSV Vaccines in Immunocompromised Adults
-
Narrated by:
-
By:
About this listen
This study investigates the antibody response to respiratory syncytial virus (RSV) vaccines in immunocompromised individuals. Researchers measured antibody levels in a cohort of immunocompromised adults after receiving either an adjuvanted or non-adjuvanted RSV vaccine. Results showed heterogeneous antibody responses, with a significant portion not achieving seroconversion or a high-titer neutralization threshold. The adjuvanted vaccine showed better results. Study limitations included a small sample size and lack of cellular data. The findings suggest a need for further investigation into optimizing RSV vaccination strategies for immunocompromised populations.
Created with NotebookLM by Google so there may be mistakes and/or errors.
PMID: 39786402
Karaba AH, Hage C, Sengsouk I, et al. Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons. JAMA 2024.